News

Endpoints News1h
Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build
As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...
Endpoints News2h
Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press
Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...
Endpoints News1h
Bio­haven gets an up to $600M in­vest­ment; Prile­nia, Fer­rer make a deal in Eu­rope
Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...
Endpoints News5h
GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer
GSK's Jemperli shows 100% efficacy in 49 MMRd rectal cancer patients, with complete disease elimination after six months' ...
Endpoints News6h
Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?
Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...
Endpoints News9h
Keytru­da around head and neck can­cer surgery cuts chance of dis­ease com­ing back
Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...
Endpoints News9h
Rev­o­lu­tion Med­i­cine’s KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta
Revolution Medicines' zoldonrasib shows 61% response rate in lung cancer patients with KRAS G12D mutations in Phase 1 trial, ...